Table 4.

Comparison of score changes at scheduled visits versus baseline between groups

Scale	Timeframe (month after last dose)	Control (n = 20), mean ± SEM	hUC-MSC (n = 19), mean ± SEM	P valueA
ADL	1	0.658 ± 1.117	2.868 ± 1.279	0.135
	3	5.975 ± 1.782	12.447 ± 2.156	0.013*
	6	10.125 ± 2.250	21.053 ± 2.860	0.003*
	12	12.775 ± 2.465	22.974 ± 2.936	0.009*
CFA	1	1.474 ± 1.455	4.158 ± 1.804	0.324
	3	7.425 ± 2.754	17.947 ± 3.317	0.021*
	6	11.925 ± 3.253	23.790 ± 3.774	0.026*
	12	15.175 ± 3.785	25.737 ± 3.947	0.061
GMFM	1	4.053 ± 3.001	− 1.316 ± 3.429	0.237
	3	15.700 ± 6.746	32.053 ± 5.028	0.062
	6	28.900 ± 8.807	59.000 ± 8.947	0.037*
	12	36.800 ± 8.802	64.526 ± 9.600	0.045*

Abbreviations: ADL activities of daily living, CFA comprehensive function assessment, GMFM gross motor function measure, hUC-MSC human umbilical cord-derived mesenchymal stem cell

^AP value was calculated by two-way ANOVA with repeated measures

*P < 0.05